Dextromilnacipran（Cat No.:I012513）is the more active enantiomer of milnacipran, functioning as a selective serotonin-norepinephrine reuptake inhibitor (SNRI). It increases the levels of serotonin and norepinephrine in the synaptic cleft, enhancing neurotransmission and mood regulation. Dextromilnacipran exhibits greater potency and selectivity compared to the racemic mixture, making it a promising candidate for the treatment of major depressive disorder (MDD) and fibromyalgia. Its pharmacological profile supports improved efficacy with potentially fewer side effects. Dextromilnacipran is used in neuropsychiatric research to study mood disorders, pain modulation, and monoaminergic signaling.